The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease
about
Bezafibrate administration improves behavioral deficits and tau pathology in P301S micePioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathologyEffects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemiaSimvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice.Aging affects the balance of neural entrainment and top-down neural modulation in the listening brain.Using genetics to enable studies on the prevention of Alzheimer's diseaseNuclear receptors in neurodegenerative diseases.Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats.Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain.Neurovascular function in Alzheimer's disease patients and experimental models.Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice.Inhibition of PPARγ during rat pregnancy causes intrauterine growth restriction and attenuation of uterine vasodilation.Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activationNeuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.Epigallocatechin Gallate Attenuates β-Amyloid Generation and Oxidative Stress Involvement of PPARγ in N2a/APP695 Cells.Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1.Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.KIBRA attains oncogenic activity by repressing RASSF1A.
P2860
Q28273620-51AA0EEF-9347-4EEA-8F00-EE1E0DF4251EQ28594423-01956685-3B7E-4CCE-97FD-25F7083BD119Q30573773-4B2BCEDD-70A7-42BB-8E74-092449DE343AQ33725859-B5AE47F4-7EB2-472E-A32D-184673191488Q33850955-06FC91F6-0A4F-4799-92FF-5796CEF68559Q34038890-F254965E-5A0D-4AAA-A3BC-1FEAA6B9131FQ34580020-57C18C67-1D44-4C3B-B6D5-BF08005CBD29Q34634984-BCC73829-1B05-405C-8E49-DC643AC727CBQ35073600-19674A60-3E75-4FD6-8DC5-9F6DE690E85DQ35088223-80CF0B98-E0A4-4905-9EFC-949611207425Q35696867-1D6B7AE0-8150-4F16-BC7C-4D6638D54FD3Q36063631-E084EB9C-738C-4111-BCBC-1A873E2164AEQ36525210-97D54B51-BC4D-4DE7-9155-8B6A6EA7D249Q37034439-A8D48792-FA45-4130-9845-53AF2AEACB28Q37728905-91E29DC5-E98D-4EB8-A17C-0915E8E322D7Q37878981-7C79E8F8-8E5A-433B-B711-2944643A4952Q38569669-43AF3E94-63F7-43AE-9521-B7C28DD6FA8DQ38728733-E5DFAAAF-BD4F-4A7D-8A28-9BC7C3B7548BQ38782659-DD78F65E-B65E-41F5-864B-EEE76C19F1D0Q38983318-ED2EF24F-E2F7-4F5B-871E-25846988974BQ48497036-7BBEDA0D-AF3F-41E7-BDB8-BFBE830D242BQ50915279-631AE39B-534B-4D81-B1FE-91E717E90D46
P2860
The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Nuclear Receptor PPARgamma ...... unction in Alzheimer's Disease
@en
The Nuclear Receptor PPARgamma ...... nction in Alzheimer's Disease.
@nl
type
label
The Nuclear Receptor PPARgamma ...... unction in Alzheimer's Disease
@en
The Nuclear Receptor PPARgamma ...... nction in Alzheimer's Disease.
@nl
prefLabel
The Nuclear Receptor PPARgamma ...... unction in Alzheimer's Disease
@en
The Nuclear Receptor PPARgamma ...... nction in Alzheimer's Disease.
@nl
P2860
P356
P1476
The Nuclear Receptor PPARgamma ...... unction in Alzheimer's Disease
@en
P2093
Edith Hamel
Nektaria Nicolakakis
P2860
P356
10.3389/FNAGI.2010.00021
P577
2010-05-21T00:00:00Z